- Home
- INTA vs PVLA Comparison
INTA vs PVLA Comparison
Compare INTA & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INTA | PVLA |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INTA | PVLA |
|---|---|---|
| Price | $27.83 | $144.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $41.43 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 896.7K | 290.1K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $504,120,000.00 | N/A |
| Revenue This Year | $15.91 | N/A |
| Revenue Next Year | $13.78 | $104,350.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.09 | N/A |
| 52 Week Low | $19.01 | $26.19 |
| 52 Week High | $47.93 | $161.38 |
Technical Indicators
Market Signals| Indicator | INTA | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 66.03 | 59.17 |
| Support Level | $20.15 | $106.07 |
| Resistance Level | $29.69 | $156.28 |
| Average True Range (ATR) | 1.36 | 10.13 |
| MACD | 0.40 | 1.21 |
| Stochastic Oscillator | 83.51 | 65.47 |
Price Performance
Historical ComparisonAbout INTA Intapp Inc.
Intapp Inc is a provider of industry-specific, cloud-based software solutions for the professional and financial services industry. It empowers private capital, legal, accounting, and consulting firms with the technology needed to meet rapidly changing client, investor, and regulatory requirements. Geographically, it derives a majority of its revenue from the United States and also has a presence in the United Kingdom and the Rest of the world.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.